Your browser doesn't support javascript.
loading
Updates on the Prognosis of Giant Cell Arteritis: A Systematic Review.
Abukanna, Abdelrahman M; Alanazi, Yousef F; Alanazi, Fahad Wadi S; Alanazi, Rayan A; Alanazi, Saif S; Alenezi, Jarah T; Alenezi, Hussam K; Alanazi, Abdulaziz Wadi S.
Afiliação
  • Abukanna AM; Internal Medicine, Northern Border University, Arar, SAU.
  • Alanazi YF; Medicine, Northern Border University, Arar, SAU.
  • Alanazi FWS; Medicine, Northern Border University, Arar, SAU.
  • Alanazi RA; Medicine, Northern Border University, Arar, SAU.
  • Alanazi SS; Medicine, Northern Border University, Arar, SAU.
  • Alenezi JT; Medicine, Northern Border University, Arar, SAU.
  • Alenezi HK; Medicine, Northern Border University, Arar, SAU.
  • Alanazi AWS; Medicine, Arabian Gulf University, Manama, BHR.
Cureus ; 15(12): e50299, 2023 Dec.
Article em En | MEDLINE | ID: mdl-38089946
ABSTRACT
Giant cell arteritis (GCA) is considered the most common type of vasculitis, especially in people aged 50 years or older, and imaging studies have helped predict its systemic nature. We conducted this review to highlight the results of the recently published articles considering the prognosis of giant cell arteritis (GCA). We searched for the relevant literature in SCOPUS, PubMed, Web of Science, and Science Direct and were included. We used Rayyan (Rayyan Systems, Cambridge, Massachusetts) throughout this systematic approach. The search resulted in twelve studies with 2600 patients with GCA diagnosis; most of them, 1853 (71.3%), were females. This systematic review found that most of the GCA patients experienced at least one relapse episode, primarily in patients younger than 75 years, with dependency on glucocorticoids, female sex, and involvement of large vessel vasculitis. We also found that stroke in GCA patients was associated with a bad prognosis. Therefore, we think more prospective studies are needed to enhance particular patient outcomes, and new therapeutic approaches using accessible biotherapies like tocilizumab and other similar medications are required.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article